SYRE Q2 2021 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M

Gross Profit

$117,0000.9% margin

Operating Income

-$7M-49.0% margin

Net Income

-$7M-49.9% margin

EPS (Diluted)

$-2.60

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$147M

Total Liabilities

$28M

Stockholders' Equity

$119M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$0	—
Gross Profit	$117,000	$0	—
Operating Income	-$7M	-$22M	+68.9%
Net Income	-$7M	-$21M	+68.1%